Personalized mRNA Melanoma Vaccine Cuts Recurrence Risk by 42%
Phase III INTerpath-001 trial data demonstrates improved outcomes by pairing intismeran with pembrolizumab after surgery
By Giovanni Sapere
2 min readHuman-Edited, AI-Assisted
In an international Phase III trial, adding the personalized therapeutic vaccine intismeran to pembrolizumab immunotherapy reduced the risk of recurrence or death by 42% in high-risk melanoma patients after surgery. Presented at the ESMO Congress 2026, the findings establish a new therapeutic approach combining tailored neoantigen targeting with immune checkpoint blockade. This medical innovation offers post-surgical protection for patients facing high chances of cancer relapse.
Trial results show marked reduction in recurrence and mortality
The Phase III INTerpath-001 clinical trial evaluated 1,137 patients with stage IIB to IV melanoma that had been surgically removed, according to findings reported by MedicalXpress. Participants had not received prior cancer drug therapies and were at high risk of disease relapse due to invasion of deeper skin layers, regional lymph node spread, or distant metastases. Representing a major healthcare innovation, the international study compared treatment using the individualized neoantigen therapy intismeran alongside pembrolizumab against treatment with pembrolizumab alone.
The combination reduced the overall risk of melanoma recurrence or death by 42% (hazard ratio 0.58; 95% confidence interval 0.45–0.75; p<0.001), as documented by MedicalXpress. Among patients who stayed disease-free past the six-month mark after beginning treatment, the risk reduction rose to 58% compared to pembrolizumab monotherapy.
“Just as email transformed how we communicate, individualized neoantigen therapy has the potential to transform how we treat cancer.”
— Professor Georgina Long AO, Medical Director at Melanoma Institute Australia
Targeting individual neoantigens with mRNA technology
Intismeran functions as a therapeutic vaccine rather than a preventative treatment, targeting patients already diagnosed with high-risk cancer. As reported by MedicalXpress, the invention is manufactured using mRNA technology based on biopsy samples collected from each patient's removed tumor. Laboratory analysis identifies specific abnormal proteins known as neoantigens, which provide a distinct molecular profile for that individual's cancer cells.
Once formulated, the mRNA instructs the patient's cells to present these tumor-specific markers directly to the immune system. While intismeran directs immune cells toward the exact targets, pembrolizumab works as an anti-PD-1 checkpoint inhibitor to remove the biochemical brakes that cancer cells use to evade detection. This dual mechanism prevents tumors from masking themselves while directing cytotoxic activity specifically against residual malignant cells, according to MedicalXpress.
Safety profile and international clinical collaboration
The addition of intismeran did not increase the baseline side effects associated with pembrolizumab, according to data published by MedicalXpress. Reported vaccine-related side effects were transient and low-grade, consisting mainly of chills, headache, and injection-site pain.
The therapy, also designated as V940 and mRNA-4157, is supported by proprietary patent portfolios and is being jointly developed by pharmaceutical firms MSD and Moderna. The INTerpath-001 study was conducted across 157 sites internationally, with study leadership headed by global principal investigator Professor Georgina Long AO of Melanoma Institute Australia and The University of Sydney, as detailed by MedicalXpress.
Read also on The Patent: Nanorobots: What it is and how it works · 3D-Printed Nitinol Braids Advance Custom Cardiovascular Implants
